吉利德科学 GILD 深 沪
已收盘 01-30 16:00:00 美东时间
141.95
+2.400
+1.72%
华盛通- 最 高142.20
- 今 开139.08
- 成交量 946.02万股
- 最 低 138.65
- 昨 收 139.55
- 总市值 1761.60亿
- 52周最高 142.20
- 市盈率 静 371.11
- 换手率 0.76%
- 52周最低 91.00
- 委 比 -83.81%
- 总股本 12.41亿
- 历史最高 142.20
- 量 比 0.98
- 振 幅 2.54%
- 历史最低 6.72
- 每 手 1
- 风险率 9.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Grants De Novo Authorization to DiaSorin for Automated Hepatitis Delta Virus Test
FDA Grants De Novo Authorization to DiaSorin for Automated Hepatitis Delta Virus Test DiaSorin S.p.A. has received U.S. Food and Drug Administration (FDA) De Novo authorization for its LIAISON XL murex anti-HDV Assay, the first fully automated laboratory test for Hepatitis Delta Virus (HDV) in the U
01-29 14:05
美国联邦医保将新增15种药物价格谈判
美国联邦医疗保险和医疗补助服务中心（Centers for Medicare and Medicaid Services，CMS）在其价格谈判计划中新增1...
01-29 00:19
BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Seagate, Nextpower
BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Seagate, Nextpower Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures rose on Wednesday, helped by gains in chip
01-28 20:05
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
Demystifying Gilead Sciences: Insights From 17 Analyst Reviews
17 analysts have expressed a variety of opinions on Gilead Sciences (NASDAQ:GIL...
01-28 05:01
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
Gilead Sciences Announces That The New England Journal Of Medicine Published The Full Results From The Phase 3 ASCENT-04/KEYNOTE-D19 Study; ASCENT-04 Met Its Primary Endpoint Of Progression-free Survival With A 35% Reduced Risk Of Disease Progression Or Death
Gilead Sciences, Inc. (NASDAQ:GILD) today announced The New England Journal of Medicine(NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy®
01-22 06:07
Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC
Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC Gilead Sciences Inc. announced the publication of full results from the Phase 3 ASCENT-04/KEYNOTE-D19 clinical trial in The New England Journal of Medicine. The study evaluated the efficacy and sa
01-22 06:00
Gilead Sciences Director Jeffrey Bluestone Reports Disposal of Common Shares
Gilead Sciences Director Jeffrey Bluestone Reports Disposal of Common Shares Jeffrey Bluestone, Director at Gilead Sciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technol
01-22 05:26
Looking Into Gilead Sciences Inc's Recent Short Interest
Gilead Sciences Inc's (NYSE:GILD) short interest as a percent of float has rise...
01-17 02:00
